Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study

Last updated: May 4, 2022
Sponsor: Shenzhen People's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Defect

Congestive Heart Failure

Hypercholesterolemia

Treatment

N/A

Clinical Study ID

NCT04730648
Among-Us study
  • Ages 18-75
  • All Genders

Study Summary

Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor could bring metabolic change in serum, in order to investigate the metabolic modification, we conduct this clinical trial.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • New diagnosis ACS patient by serum biomarker and coronary arteriography.

Exclusion

Exclusion Criteria:

  • Severe renal dysfunction acute or chronic bacterial and viral infections sleep apneacancer

Study Design

Total Participants: 100
Study Start date:
April 22, 2021
Estimated Completion Date:
April 23, 2023

Connect with a study center

  • Tangzhiming Li

    Shenzhen, Guangdong 518020
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.